Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB ) Q4 2024 Earnings Conference Call: Key Highlights
On March 4, 2025, Y-mAbs Therapeutics, Inc. held its earnings conference call for the fourth quarter and full year 2024. The call was led by Courtney Dugan, Head-IR, Michael Rossi, President & CEO, Doug Gentilcore, Senior VP & Head of DANYELZA Business Unit, Natalie Tucker, Radiopharmaceutical Business Unit Head, and Peter Pfreundschuh, CFO. The following are key highlights from the call:
Financial Results
During the call, the company reported its financial results for Q4 2024 and the full year. Revenue for the year came in at $350 million, representing a 35% increase compared to 2023. Net loss for the year was reported at $125 million, which was an improvement from the $150 million net loss reported in 2023. The company ended the year with cash and cash equivalents of $375 million.
Business Updates
Doug Gentilcore provided updates on the DANYELZA business unit, noting that the company had received FDA approval for an expanded indication for the treatment of relapsed/refractory Hodgkin lymphoma. This expansion is expected to lead to increased sales and revenue for the company. Natalie Tucker discussed the progress of the Radiopharmaceutical Business Unit, highlighting the successful completion of a Phase 1 study for a new radioligand therapy and the initiation of a Phase 2 study.
Collaborations and Partnerships
Michael Rossi discussed several collaborations and partnerships that the company has entered into. One of these partnerships is with Merck KGaA, Darmstadt, Germany, to develop and commercialize a new class of therapeutic antibodies. Another partnership is with the University of California, San Francisco (UCSF) to develop new radiopharmaceutical therapies for the treatment of cancer. These collaborations are expected to drive innovation and growth for the company.
Impact on Individual Investors
The strong financial performance and promising business updates from Y-mAbs Therapeutics’ Q4 2024 earnings call have led to a positive reaction from the market. Shares of the company have seen a significant increase in value since the call, providing a potential opportunity for individual investors looking to capitalize on this growth.
Impact on the World
The advancements made by Y-mAbs Therapeutics in the field of therapeutic antibodies and radiopharmaceutical therapies have the potential to revolutionize the way cancer is treated. The company’s expanded indication for DANYELZA and successful collaborations with Merck KGaA and UCSF could lead to new and more effective treatments for various types of cancer, ultimately improving the lives of millions of people around the world.
Conclusion
Y-mAbs Therapeutics’ Q4 2024 earnings call provided investors with encouraging financial results and promising business updates. The company’s focus on innovation and growth, as evidenced by its collaborations and partnerships, positions it well for continued success in the future. With the potential to revolutionize cancer treatment through its therapeutic antibodies and radiopharmaceutical therapies, Y-mAbs Therapeutics is a company to watch in the biotech industry.
- Y-mAbs Therapeutics reported strong financial results for Q4 2024 and the full year, with revenue of $350 million and net loss of $125 million.
- The company received FDA approval for an expanded indication for DANYELZA, which is expected to lead to increased sales and revenue.
- The Radiopharmaceutical Business Unit successfully completed a Phase 1 study and initiated a Phase 2 study for a new radioligand therapy.
- The company entered into several collaborations and partnerships, including with Merck KGaA and UCSF, to drive innovation and growth.
- Individual investors have reacted positively to the earnings call, leading to an increase in the value of Y-mAbs Therapeutics’ shares.
- The company’s advancements in therapeutic antibodies and radiopharmaceutical therapies have the potential to revolutionize the way cancer is treated, ultimately improving the lives of millions of people around the world.
